SeraCare Life Sciences and TOMA Biosciences Enter Into Co-development Partnership

By April 22, 2016Press Releases

TOMA Biosciences to use Seraseq™ biosynthetic reference material technology in development and validation of their TOMA OS-Seq™ reagent kits
Milford, Massachusetts, April 20, 2016 – SeraCare Life Sciences, a manufacturer and leading partner to global in vitro diagnostics manufacturers, and TOMA Biosciences, a genomics company providing the most effective sequencing solution to identify clinically meaningful changes in the DNA of cancer tumors, announce today a co-development partnership during the 2016 American Association of Cancer Research in New Orleans.
Under the terms of the agreement, SeraCare will provide TOMA Biosciences access to their Seraseq™ Solid Tumor Mutation Mix reference mate rial technology to support the development and validation of the TOMA OS-Seq™ comprehensive solid tumor gene analysis kit, as well as their upcoming PlasmaSeq™ liquid biopsy test.
Read Full Article